| Returns | 1W : -3.3% , 1M : 4%,1Y : 130.4% |
| Peers & Returns | 1W | 1M | 1Y |
| IPCA LABORATORIES | -3.3% | 4% | 130.4% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.5% | -5.5% | 23.6% |
| DRREDDYS LABORATORIES | 15.7% | 14.5% | 95% |
| DIVIS LABORATORIES | -0.8% | -2.7% | 105.6% |
| CIPLA | 3.4% | 0.9% | 72.2% |
| PIRAMAL ENTERPRISES | -5.4% | -10.5% | -26.1% |
| LUPIN | 4% | 6% | 42.1% |
| AUROBINDO PHARMA | -3.3% | -7.6% | 31.5% |
| TORRENT PHARMACEUTICALS | -5.1% | -4.2% | 66.9% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S PEG |
43.59 6.32 5.46 1.31 |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
248% 110% 127% |
| Year | Debt/Equity ratio | |
|---|---|---|
|
Debt/Equity ratio analysis
For Banking industry, Good = Ratio less than 13 Average = Ratio between 13 and 15 Bad = Ratio greater than 15 For all non-Banking industries, Good = Ratio less than 0.4 Average = Ratio between 0.4 and 0.6 Bad = Ratio greater than 0.6 Worst is considered between Standalone & Consolidated |
Standalone | Consolidated |
|
2020 2019 2018 Avg_3yrs |
0.12 0.14 0.23 0.16 |
0.13 0.15 0.23 0.17 |
|
[Last Annual Data : Mar2020]
|
||
| Pledged Shares |
0 % |
|---|---|
| As of : July 14,2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| Parameter | 1 Qtr Growth | 4 Qtr Growth |
|---|---|---|
|
Revenue Op Profit EBIDT Net Income |
47.82% 191.05% 251.17% 255.07% |
46.91% 179.59% 228.61% 243.54% |
| QtrlyTrend |
8
Quarterly Trend analysis
The growth rate score are assigned as under: If ratio's 1Q growth is +ve, then 1. If -ve, then -1. If ratio's 4Q growth is +ve, then 1.If -ve, then -1. Growth Score= Sum of all the above scores for Revenue, Operating Profit and Net Income. Interpretation Good = Growth Score >=4 Neutral = Growth Score between 0 and 4 Bad = Growth Score less than 0 |
|
| Latest Qtr: Jun2020 | ||
